PRESTIGE BIOPHARMA TO OPERATE NEW VACCINE PRODUCTION CENTRE IN SOUTH KOREA

KUALA LUMPUR, April 20 -- Prestige Biopharma Limited (PBP), a company specialising in antibody therapeutics development, will introduce a vaccine development and production centre into its core business.

PBP is on target to complete the construction of its global-scale vaccine production facility in Osong, South Korea with total area of approximately 8,500 m² inside the Campus 2 facility of its affiliated company Prestige Biologics. 

The facility is projected to start operations from August, utilising Prestige Biologics’ unmatched engineering service for expedited establishment with cutting-edge technology.

PBP will utilise Prestige Biologics’ proprietary ALITA Smart BioFactory™, the world’s first smart factory system in biomanufacturing designed based on digital artificial intelligence, reducing human or process related errors.

Based on a statement, the system will also enable fast and convenient change-over to maximise efficiency when catering for multiple products and manufacturing processes.

The total production capacity of the vaccine centre is 100,000 litres, comprising 50 units of 2,000 litre single-use bioreactors with accompanying seed train and downstream purification capacities.

With this global-scale production capacity, the centre will contribute to the growing global demands of vaccine development and production in response to infectious diseases such as COVID-19.

PBP will participate in a consortium led by Huons Global in the production of Russia's Sputnik V COVID-19 vaccine as the Drug Substance manufacturing centre.

-- BERNAMA